All of us here at Sentry have been busy gearing up for the annual 340B Coalition Winter Conference, which kicks off February 16 and will take place virtually this year. Our theme for the conference is expect progress, and we’re excited to…

Now that we’ve all endured one of the most difficult years in recent memory, we welcome 2021, complete with a new president, administration and Congress. As we move past a violent and tumultuous transition, what will these changes mean to our healthcare system and to the 340B program we all know and support?

While 2020 has been a difficult year in healthcare for many reasons, it’s also been a year of tremendous growth for Sentry’s training and education offerings. We’ve made great strides toward our goal of educating our customers on how to…

Interregnum is an arcane Latin expression for “between reigns.” In U.S. politics, it is the interval between the end of one president's time as leader and the coming to power of the next president.

There’s no understating the impact that delayed or denied claims can have on your organization’s bottom line – particularly claims in which clinicians at hospitals and health systems administer medication as part of the treatment plan.

In this month’s 340Buzz, we’ll look at a flurry of legislative activities related to 340B: bills introduced, letters proffered, new rules for alternative dispute resolution, most-favored-nation pricing and Medicare Part D rebates. We’ll also share some of the buzz on who may be joining the new administration in key health policy roles.

Sentry Data Systems is proud to announce that its Sentinel platform now features fully seamless integration with each of the so-called ‘Big Three’ drug wholesalers: McKesson, AmerisourceBergen and Cardinal Health.

By the time you read this, much will have changed. A new Supreme Court Justice has been confirmed, shifting the political balance of the court. A presidential election will transpire shortly, with its many implications for the Affordable Care Act, the 340B program, drug pricing, Medicaid and Medicare – no matter who wins. While we wait for change, we’ll take a closer look at some important October events – from continued actions by manufacturers, congressional actions and the potential impact of the Supreme Court.

Safety net healthcare providers are under enormous pressure on multiple fronts these days. The 340B Drug Pricing Program is under assault from drug manufacturers, CMS’s proposed 340B reimbursement cuts are tied up in the courts and the COVID-19 pandemic is putting the squeeze on finances and staffing levels. With all the chaos and uncertainty, it’s especially important for covered entities to capture as much savings as possible to optimize their 340B program.